Significant events during the quarter Significant events after the quarter

• On October 31, the journal · No significant events were reported

Respiratory Research published an in after the end of the quarter.
-vitro study from the Medical
University of Innsbruck which shows
that ColdZyme blocks the widespread
and highly transmissible omicron
variants BA.4 and BA.5 from adhering
to and infecting human cells.
According to the researchers who
conducted the study, this finding
means the possibility that ColdZyme
can be applied to prevent the spread
of SARS-CoV-2. Continued clinical
trials are needed to confirm the
effect in-vivo.

Other events
during the
quarter

• In

November, the
University of
Kent (UK)
initiated a
double-blind,
placebo
-controlled
clinical study
to explore the
preventative
effects of
ColdZyme on
upper
respiratory
tract
infections in
elite athletes.
The study
builds on a
previous 2020
study from the
same research
group, which
showed that
treatment with
ColdZyme can
reduce the
number of lost
training days.
The goal is to
present the
study in the
fall of 2023
before the
upcoming cold
season.

Fourth January-December
quarter

• Net sales · Net sales reached SEK 48.9 (57.2) million.

reached SEK · The operating result totaled SEK -68.2 (-45.2) million.
16.6 (18.7) · The operating result includes non-recurring expenses of SEK
million. 14.2 million attributable to the renegotiation of contracts

• The with two of the company's partners.

operating · Earnings per share, basic and diluted, were
result SEK -0.44 (-0.31).
totaled SEK · Cash flow from operating activities for the period totaled
-21.6 (-10.5) SEK -65.4 (-35.9) million. Cash flow was impacted by payment of
million. the one-off compensation to partners totaling SEK 18.5 million.

• The · Cash flow from financing activities totaled SEK 88.2

operating million, of which SEK 69.0 million relates to the rights issue
result in September.
includes non · Net cash totaled SEK 28.4 (29.0) million.
-recurring
expenses of
SEK 5.6
million
attributable
to the
renegotiation
of contracts
with one of
the company's
partners.

• Earnings

per share,
basic and
diluted, were
SEK -0.14 (
-0.07).

• Cash flow

from
operating
activities
totaled SEK
-27.7 (-6.6)
million. Cash
flow was
affected by
payment of
one-off
compensation
to partners
totaling SEK
18.5 million.

"At the end of the fourth quarter 2022 and the beginning of the first quarter 2023, we have seen that sales are stronger compared with the same period a year ago. Sales to consumers in Sweden are growing and our market share remains strong. Sales to our partners outside Sweden are expected to grow again as our partners' inventories decrease following the return of common colds. A tough 2022 led to improved structures and processes and closer collaboration with our partners. That is why I now look with confidence to 2023. Enzymatica is ready for a comeback", said Claus Egstrand, CEO of Enzymatica. 

The full year-end report is available on: www.enzymatica.com/investors/financial-reports

This information is information that Enzymatica is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08:30 a.m. CET
on February 17, 2023.

For more information, please contact:

Claus Egstrand, Chief Executive Officer, Enzymatica AB
Phone: +44 7780 22 8385 | Email: claus.egstrand@enzymatica.com

Stefan Olsson, Communication Manager, Enzymatica AB
Phone: +46 708 55 11 85 | Email: stefan.olsson@enzymatica.com
Enzymatica AB is headquartered in Lund, Sweden, and is listed on Nasdaq First North Growth Market. For more information, please visit www.enzymatica.se. Enzymatica's Certified Adviser is Erik Penser Bank. Tel: +46 8 463 83 00 Email: certifiedadviser@penser.se.